Financial Gravity Asset Management Inc. Sells 14,445 Shares of Astrazeneca Plc $AZN

Financial Gravity Asset Management Inc. reduced its position in shares of Astrazeneca Plc (NYSE:AZN) by 30.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,313 shares of the company’s stock after selling 14,445 shares during the quarter. Astrazeneca accounts for approximately 1.1% of Financial Gravity Asset Management Inc.’s holdings, making the stock its 24th biggest position. Financial Gravity Asset Management Inc.’s holdings in Astrazeneca were worth $5,846,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cibc World Market Inc. grew its stake in shares of Astrazeneca by 21.5% during the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after acquiring an additional 11,398 shares during the period. TD Asset Management Inc grew its stake in shares of Astrazeneca by 20.0% during the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after acquiring an additional 181,273 shares during the period. AMG National Trust Bank lifted its holdings in Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Assetmark Inc. lifted its holdings in Astrazeneca by 6.5% in the 3rd quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock worth $23,813,000 after purchasing an additional 19,020 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in Astrazeneca by 6.6% in the 3rd quarter. US Bancorp DE now owns 242,181 shares of the company’s stock worth $18,581,000 after purchasing an additional 15,065 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Stock Performance

NYSE:AZN opened at $178.79 on Friday. The stock’s fifty day moving average is $189.26 and its 200 day moving average is $185.98. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The firm has a market capitalization of $277.28 billion, a PE ratio of 26.85, a PEG ratio of 1.56 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. On average, sell-side analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research analyst reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Weiss Ratings reissued a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.